Core Insights - The company reported strong sales growth for the first nine months of 2025, prompting an upward revision of its full-year financial guidance [1][2] - The CEO highlighted robust performance across three therapeutic areas, with increasing contributions from the rare liver disease segment [1] - The company is optimistic about the Phase II LANTIC trial data for its innovative long-acting molecule IPN10200 in the aesthetic medicine sector [1] Financial Performance - For the first nine months of 2025, the company achieved a year-on-year sales growth of approximately 10.0%, up from a previous expectation of over 7.0% [2] - The company has adjusted its full-year financial guidance based on strong performance metrics [2] Acquisition Details - The company signed a final equity acquisition agreement to acquire ImCheck Therapeutics, a French biotech firm focused on next-generation cancer immunotherapy [2] - The acquisition centers on the ICT01 project, which targets acute myeloid leukemia (AML) and is expected to enter Phase IIb/III trials in 2026 [2] - The deal includes an upfront cash payment of €350 million, with additional payments contingent on regulatory approvals and sales milestones [2]

Core Insights - Ipsen is acquiring ImCheck Therapeutics for €350 million ($406.6 million) with potential total transaction value reaching €1 billion ($1.16 billion) based on regulatory milestones and sales targets [1][2][3] Group 1: Transaction Details - The acquisition will be executed by Ipsen SAS' fully owned subsidiary and is expected to close by the end of Q1 2026, pending regulatory approvals [2] - Legal counsel for Ipsen is provided by Allen & Overy Shearman, while ImCheck has engaged Centerview Partners as its exclusive financial advisor [2][3] Group 2: Focus of Acquisition - The primary focus of the acquisition is ImCheck's ICT01, a Phase I/II program targeting acute myeloid leukaemia patients not suitable for intensive chemotherapy [3] - ICT01 received orphan drug status from both the European Medicines Agency and the US Food and Drug Administration in July 2025 [3] Group 3: Strategic Implications - Ipsen's CEO highlighted the acquisition as an opportunity to expand its oncology pipeline and emphasized confidence in advancing ICT01 into a Phase IIb/III trial in 2026 [4]

Core Points - Ipsen has announced a definitive agreement to acquire ImCheck Therapeutics, a French biotechnology company specializing in next-generation immuno-oncology therapies, focusing on the ICT01 program for treating acute myeloid leukemia (AML) [1][5][6] - The acquisition aims to enhance Ipsen's oncology R&D portfolio and is expected to facilitate the launch of a Phase IIb/III trial for ICT01 in 2026, leveraging promising data from ongoing clinical trials [3][6] Transaction Details - The acquisition involves a payment of €350 million at closing, with potential total payments reaching up to €1 billion contingent on regulatory approvals and sales milestones [5][6] - The transaction is expected to be finalized by the end of Q1 2026, subject to customary closing conditions [7] Clinical Program Insights - ICT01 is a first-in-class monoclonal antibody targeting BTN3A, showing high therapeutic response rates in ongoing Phase I/II trials, particularly for patients ineligible for intensive chemotherapy [2][3][6] - The EVICTION trial data indicated that the combination of ICT01 with venetoclax and azacitidine resulted in nearly double the response rate compared to historical data for standard care [3][6] Company Background - Ipsen is a global biopharmaceutical group focused on developing innovative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of experience in drug development [11] - ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, with the potential to transform treatments in oncology and other fields [12][14]

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing purchase price of 350 ...